1. Home
  2. LCFY vs NVNO Comparison

LCFY vs NVNO Comparison

Compare LCFY & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.30

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$9.88

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
NVNO
Founded
2009
1987
Country
Australia
United States
Employees
18
33
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCFY
NVNO
Price
$4.30
$9.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.8K
6.0K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$140.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.30
52 Week High
$13.98
$13.44

Technical Indicators

Market Signals
Indicator
LCFY
NVNO
Relative Strength Index (RSI) 45.30 38.04
Support Level $4.07 $9.81
Resistance Level $4.84 $12.69
Average True Range (ATR) 0.19 0.69
MACD -0.05 -0.24
Stochastic Oscillator 23.53 14.27

Price Performance

Historical Comparison
LCFY
NVNO

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: